425 related articles for article (PubMed ID: 15651756)
1. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
[TBL] [Abstract][Full Text] [Related]
2. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
4. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
7. Using ritonavir with indinavir in cases of virologic failure.
TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
[No Abstract] [Full Text] [Related]
8. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
[TBL] [Abstract][Full Text] [Related]
9. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
[TBL] [Abstract][Full Text] [Related]
10. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
[TBL] [Abstract][Full Text] [Related]
12. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Duvivier C; Myrto A; Marcelin AG; Ghosn J; Ait-Mohand H; Schneider L; Agher R; Bricaire F; Costagliola D; Calvez V; Peytavin G; Katlama C
Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
[TBL] [Abstract][Full Text] [Related]
15. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
Katner HP; Paar DP; Nadler JP; Jensen EH; Wilson HM; Finn TS; Petruschke RA; Zeldin RK
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):483-7. PubMed ID: 12473836
[TBL] [Abstract][Full Text] [Related]
16. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
[TBL] [Abstract][Full Text] [Related]
17. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
[TBL] [Abstract][Full Text] [Related]
18. Ritonavir and indinavir one year later.
TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
[No Abstract] [Full Text] [Related]
19. Simplifying drug regimens.
HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
[TBL] [Abstract][Full Text] [Related]
20. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
